A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program.

Trial Profile

A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms LONGTERMS
  • Sponsors Novartis
  • Most Recent Events

    • 19 Jun 2018 Results assessing MRI outcomes presented at the 4th Congress of the European Academy of Neurology.
    • 19 Dec 2017 Results of a substudy (n=13) assessing seminal concentration of fingolimod and fingolimod-phosphate in multiple sclerosis male patients from TRANSFORMS extension (NCT00340834) or the LONGTERMS study (NCT01281657), published in the Clinical Pharmacology in Drug Development Journal.
    • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top